Healthcare Industry News: Arbor Pharmaceuticals
News Release - January 7, 2009
Arbor Pharmaceuticals Announces Closing of Series A Financing and Initial Deployment of the Company's Pediatric Sales Force
RALEIGH, N.C., Jan. 7 -- (Healthcare Sales & Marketing Network) -- Arbor Pharmaceuticals ("Arbor"), an emerging specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company recently closed its Series A financing. This latest round of investment capital will support the launch of Arbor's third product and facilitate continued growth of the company and its current and pipeline products. The Series A funding was participated in by several new investors in addition to the company's original investment group. Since the founding of Arbor in 2006 the company has launched two novel prescription products for ear infections (ZINOTIC® and NEOTIC®) and is developing a pipeline of unique nonantibiotic products for common pediatric illnesses."This new round of funding will allow the company to continue on its significant growth trajectory by introducing new and important treatment options for children. We are grateful to the company's investors for recognizing the significant value that Arbor has created as an emerging leader in pediatric pharmaceuticals. Arbor is well positioned to continue to introduce important and novel pediatric treatment options and further establish Arbor as a leader in the growing pediatric pharmaceuticals market," says Jarrett Disbrow, President & CEO of Arbor.
In addition to completing the Series A financing Arbor has recently deployed a specialty sales force focused on promoting the company's products to pediatricians across the United States. The company also has a promotional agreement with a partner company to promote Arbor's products in several markets. Arbor's products are now being promoted in more than 25 major U.S. metropolitan areas. The company plans to expand its sales force in the coming months.
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty pharmaceutical company focused exclusively on the growing pediatric market. Arbor actively licenses, develops and commercializes pediatric products initially focused on nonantibiotic products for the treatment of various ear infections and currently markets two patented products, ZINOTIC® and NEOTIC®. The company intends to become the leading pediatric pharmaceutical company by developing and commercializing a robust pipeline of late-stage products for common pediatric conditions. Arbor will launch a novel treatment option for recurrent middle ear infections in early 2009.
To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.
Source: Arbor Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
